Saturday 17 October 2026
Export OSTX’s income statement to Excel — free account
OS Therapies Incorporated
OSTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 5.26% and free cash flow fell 134.4%, each against the same quarter a year earlier.
1.32
0.09
−6.38%
Follow OSTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(1,248.03%) | 614.26% | 469.98% | 1,129.52% | |
| (334.55%) | (464.58%) | (610.85%) | (389.65%) | ||
ROIC |
(434.52%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1,004.35% | 251.58% | 220.00% | 231.59% | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(0.40) | (0.49) | (0.40) | (0.42) | |
Free Cash Flow |
(12.88) | (14.24) | (15.36) | (18.53) | |
| Other line items | |||||
Cash ROIC |
(195.65%) | 299.44% | 173.84% | 174.20% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | (26.09) | (71.46) | |
Operating CF/Net income |
0.70 | 0.50 | 0.44 | 0.47 | |
Depreciation/Fixed assets |
74.84 | 560.28 | 885.50 | 1,465.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.40) | (0.49) | (0.40) | (0.42) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates